To the Editor-Rolain et al [1] report a patient colonized with a colistinresistant Acinetobacter baumannii strain after colistin therapy without clinical signs of infection, pointing out the low virulence of A. baumannii with acquired resistance to colistin, as previously hypothesized by our group [2] . Moreover, Rolain et al raise the possibility of compensatory mutations restoring the virulence in colistin-resistant A. baumannii. We now describe a patient infected by colistin-susceptible A. baumannii whose organism acquired resistance to colistin after colistin therapy without losing its infecting capacity.
A 39-year-old man with previous surgical resection of a craniopharyngioma in 1990 was admitted on 7 October 2009 with symptoms of acute hydrocephalus. He was treated with external ventricular cerebrospinal fluid (CSF) decompression. On day 8 following the procedure, the patient presented CSF leakage at the surgical wound and on day 11 had headache with a turbid and xanthochromic CSF, with 5360 cells/lL (98% neutrophils), and 0.028 g/L glucose; treatment with vancomycin (500 mg/intravenously [iv]/ 6 hours) and meropenem (1 g/iv/8 hours) was prescribed. A. baumannii was isolated from CSF and was susceptible to colistin, tigecycline, amikacin, gentamicin, and tobramycin, and resistant to ceftazidime, cefotaxime, cefepime, imipenem, meropenem, piperacillin, ticarcillin, rifampicin, sulbactam, and ciprofloxacin. On day 14, vancomycin and meropenem were discontinued and colistin (2 3 10 6 U/iv/6 hours) was started. On day 23, CSF characteristics remained similar and A. baumannii was again isolated with changes in its susceptibility/resistance profile: susceptible to sulbactam, tigecycline, minocycline, amikacin, gentamicin, and tobramycin, and This case report confirms, as Rolain et al have described [1] , that colistinresistant A. baumannii strains may be selected in vivo by the use of colistin but that such acquisition of resistance does not always indicate a bacterial fitness cost. Moreover, the acquisition of resistance to colistin in A. baumannii in this case led us to change the antibiotic resistance profile, as the isolate became susceptible to cefepime and sulbactam.
Little is known about the resistance to colistin in A. baumannii. It has been associated with mutations in the PmrAB 2-component system [3] , which produce modifications in bacterial lipopolysaccharide that lead to an addition of phosphoetanolamine to lipid A, conferring colistin resistance [4] . Acquisition of polymyxin resistance is associated with differences in protein expression: 35 proteins were downregulated in the colistin-resistant strain, including outer membrane proteins, chaperones, protein biosynthesis factors, and metabolic enzymes [5] , which translated to a loss of biological fitness and virulence [2] . On the other hand, high-level colistin resistance in A. baumannii has been linked to a complete loss of lipopolysaccharide due to the inactivation of the A. baumannii lipid A biosynthesis, as an effect of mutations in 1 of the first 3 genes of the lipid A biosynthesis pathway (lpxA, lpxC, and lpxD) [6] , or as the inactivation of the lpxA and lpxC genes by the insertion sequence element ISAba11 [7] . The acquisition of polymyxin resistance where a complete loss of lipopolysaccharide is involved is associated with a decrease in the outer membrane integrity, and to an increased susceptibility of these strains to other antibiotics, including cefepime, as in the case we reported here, and some that are usually active only against Gram-positive bacteria [6, 8] .
In summary, resistance to colistin in clinical strains of A. baumannii, although still sporadic, may occur due to the increasing use of colistin. Although colistin resistance may suggest a fitness cost for bacteria, the case we describe here indicates that it does not always occur, as unidentified compensatory mutations may appear to maintain the virulence of A. baumannii. 
